HRP20220829T1 - Kristalni spojevi - Google Patents
Kristalni spojevi Download PDFInfo
- Publication number
- HRP20220829T1 HRP20220829T1 HRP20220829TT HRP20220829T HRP20220829T1 HR P20220829 T1 HRP20220829 T1 HR P20220829T1 HR P20220829T T HRP20220829T T HR P20220829TT HR P20220829 T HRP20220829 T HR P20220829T HR P20220829 T1 HRP20220829 T1 HR P20220829T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystal form
- xrpd
- group
- pattern
- ray powder
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000013078 crystal Substances 0.000 claims 15
- 238000000634 powder X-ray diffraction Methods 0.000 claims 11
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- ACVMJAJGCQUPKX-LIOBNPLQSA-N (1r,5s)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane;hydrochloride Chemical compound Cl.C1=CC=CC2=CC([C@@]34CNC[C@H]4C3)=CC=C21 ACVMJAJGCQUPKX-LIOBNPLQSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181174P | 2015-06-17 | 2015-06-17 | |
| EP19196556.5A EP3597189B1 (en) | 2015-06-17 | 2016-06-17 | Crystalline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220829T1 true HRP20220829T1 (hr) | 2022-12-23 |
Family
ID=57546597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220829TT HRP20220829T1 (hr) | 2015-06-17 | 2016-06-17 | Kristalni spojevi |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9708261B2 (https=) |
| EP (3) | EP4049997A1 (https=) |
| JP (4) | JP6896651B2 (https=) |
| KR (1) | KR102593783B1 (https=) |
| CN (3) | CN107921021A (https=) |
| AU (2) | AU2016279075C1 (https=) |
| CA (2) | CA3200692A1 (https=) |
| CY (1) | CY1125352T1 (https=) |
| DK (1) | DK3597189T3 (https=) |
| ES (1) | ES2922158T3 (https=) |
| HK (1) | HK1247125A1 (https=) |
| HR (1) | HRP20220829T1 (https=) |
| HU (1) | HUE059348T2 (https=) |
| LT (1) | LT3597189T (https=) |
| MX (2) | MX387591B (https=) |
| MY (1) | MY194868A (https=) |
| NZ (2) | NZ776973A (https=) |
| PH (1) | PH12017502324A1 (https=) |
| PL (1) | PL3597189T3 (https=) |
| PT (1) | PT3597189T (https=) |
| SA (1) | SA517390552B1 (https=) |
| SG (1) | SG10201911417PA (https=) |
| SI (1) | SI3597189T1 (https=) |
| TW (1) | TWI751998B (https=) |
| WO (1) | WO2016205762A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ592836A (en) | 2005-07-27 | 2013-01-25 | Dov Pharmaceutical Inc | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| KR20160101012A (ko) | 2013-12-09 | 2016-08-24 | 뉴로반스, 인크. | 신규 조성물 |
| SG10201911417PA (en) | 2015-06-17 | 2020-01-30 | Otsuka America Pharmaceutical Inc | Crystalline compounds |
| WO2019114394A1 (zh) * | 2017-12-11 | 2019-06-20 | 苏州科睿思制药有限公司 | Eb-1020的晶型及其制备方法和用途 |
| JP7704681B2 (ja) * | 2019-10-16 | 2025-07-08 | 大塚製薬株式会社 | センタナファジンの製造方法 |
| WO2022256215A1 (en) | 2021-05-31 | 2022-12-08 | Teva Pharmaceuticals International Gmbh | Solid state form of centanafadine hcl and process for preparation thereof |
| US12502358B1 (en) | 2024-08-13 | 2025-12-23 | Innovate Therapeutics Llc | Centanafadine multiphasic controlled-release pharmaceutical formulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL376604A1 (pl) | 2002-11-08 | 2006-01-09 | Dov Pharmaceuticals, Inc. | Polimorfy chlorowodorku bicifadyny |
| PL1740593T3 (pl) | 2004-04-19 | 2016-09-30 | Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I | |
| US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| MX2007001827A (es) | 2004-08-18 | 2007-04-23 | Dov Pharmaceutical Inc | Nuevas sustancias polimorfas de azabiciclohexano. |
| US20070082939A1 (en) | 2005-07-26 | 2007-04-12 | Lippa Arnold S | Methods and compositions for the treatment of neuropathies and related disorders |
| NZ592836A (en) | 2005-07-27 | 2013-01-25 | Dov Pharmaceutical Inc | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| US20080058535A1 (en) | 2006-07-25 | 2008-03-06 | Zhengming Chen | Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes |
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| PT2819516T (pt) * | 2011-07-30 | 2020-03-25 | Otsuka America Pharmaceutical Inc | Utilização de (1r,5s)-(+)-1-(naftalen-2-il)-3-azabiciclo[3.1.0]hexano no tratamento de doenças afectadas por neurotransmissores monoaminas |
| US20140206740A1 (en) * | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| US20140228421A1 (en) | 2011-09-07 | 2014-08-14 | Anthony McKinney | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters |
| KR20160101012A (ko) | 2013-12-09 | 2016-08-24 | 뉴로반스, 인크. | 신규 조성물 |
| SG10201911417PA (en) | 2015-06-17 | 2020-01-30 | Otsuka America Pharmaceutical Inc | Crystalline compounds |
-
2016
- 2016-06-17 SG SG10201911417PA patent/SG10201911417PA/en unknown
- 2016-06-17 HR HRP20220829TT patent/HRP20220829T1/hr unknown
- 2016-06-17 AU AU2016279075A patent/AU2016279075C1/en active Active
- 2016-06-17 CA CA3200692A patent/CA3200692A1/en active Pending
- 2016-06-17 LT LTEP19196556.5T patent/LT3597189T/lt unknown
- 2016-06-17 KR KR1020187001083A patent/KR102593783B1/ko active Active
- 2016-06-17 PT PT191965565T patent/PT3597189T/pt unknown
- 2016-06-17 EP EP22164478.4A patent/EP4049997A1/en active Pending
- 2016-06-17 HU HUE19196556A patent/HUE059348T2/hu unknown
- 2016-06-17 HK HK18106861.3A patent/HK1247125A1/zh unknown
- 2016-06-17 EP EP16812592.0A patent/EP3310352A4/en not_active Ceased
- 2016-06-17 CN CN201680035027.1A patent/CN107921021A/zh active Pending
- 2016-06-17 NZ NZ776973A patent/NZ776973A/en unknown
- 2016-06-17 NZ NZ739044A patent/NZ739044A/en unknown
- 2016-06-17 PL PL19196556.5T patent/PL3597189T3/pl unknown
- 2016-06-17 ES ES19196556T patent/ES2922158T3/es active Active
- 2016-06-17 JP JP2017565236A patent/JP6896651B2/ja active Active
- 2016-06-17 CA CA2989431A patent/CA2989431C/en active Active
- 2016-06-17 MX MX2017016430A patent/MX387591B/es unknown
- 2016-06-17 EP EP19196556.5A patent/EP3597189B1/en active Active
- 2016-06-17 CN CN202310843667.7A patent/CN117466800A/zh active Pending
- 2016-06-17 WO PCT/US2016/038256 patent/WO2016205762A1/en not_active Ceased
- 2016-06-17 US US15/186,415 patent/US9708261B2/en active Active
- 2016-06-17 MY MYPI2017704811A patent/MY194868A/en unknown
- 2016-06-17 CN CN202310848120.6A patent/CN117088802A/zh active Pending
- 2016-06-17 SI SI201631552T patent/SI3597189T1/sl unknown
- 2016-06-17 DK DK19196556.5T patent/DK3597189T3/da active
- 2016-12-21 TW TW105142467A patent/TWI751998B/zh active
-
2017
- 2017-06-01 US US15/611,580 patent/US9856217B2/en active Active
- 2017-11-21 US US15/820,241 patent/US10280141B2/en active Active
- 2017-12-14 SA SA517390552A patent/SA517390552B1/ar unknown
- 2017-12-15 PH PH12017502324A patent/PH12017502324A1/en unknown
- 2017-12-15 MX MX2020009949A patent/MX2020009949A/es unknown
-
2019
- 2019-03-11 US US16/298,179 patent/US10800740B2/en active Active
-
2020
- 2020-08-14 US US16/993,648 patent/US11299458B2/en active Active
-
2021
- 2021-01-19 AU AU2021200314A patent/AU2021200314B2/en active Active
- 2021-06-09 JP JP2021096354A patent/JP7244575B2/ja active Active
-
2022
- 2022-07-11 CY CY20221100470T patent/CY1125352T1/el unknown
-
2023
- 2023-03-09 JP JP2023036730A patent/JP7583851B2/ja active Active
-
2024
- 2024-11-01 JP JP2024192608A patent/JP2025022896A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220829T1 (hr) | Kristalni spojevi | |
| HRP20220182T1 (hr) | Kristalni oblici inhibitora prolil hidroksilaze | |
| NZ742200A (en) | Treatment of osteoarthritis | |
| MX2008013782A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen. | |
| PE20250001A1 (es) | Formas cristalinas novedosas | |
| PH12017502001A1 (en) | Amido-substituted cyclohexane derivatives | |
| NZ716840A (en) | Combination formulation of two antiviral compounds | |
| HRP20211511T1 (hr) | Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida | |
| WO2016134301A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| AR084309A1 (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| UA129695C2 (uk) | Спосіб отримання та кристалічні форми проміжного продукту в синтезі інгібітора mdm2 | |
| HRP20220759T1 (hr) | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti | |
| MX376822B (es) | Composicion de liberacion demorada que comprende biguanida. | |
| CN103717571B8 (zh) | 9‑氨基甲基取代的四环素类化合物 | |
| MX2019008438A (es) | Moduladores del receptor de estrogeno. | |
| HRP20192132T1 (hr) | Antagonist nk-1/nk-3 receptora za liječenje valunga | |
| EA201590562A1 (ru) | Бензамиды | |
| AR066158A1 (es) | COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE. | |
| EA201492091A1 (ru) | Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| HRP20240694T1 (hr) | Inhibitori arginaze i postupci njihove upotrebe | |
| JP2016515550A5 (https=) | ||
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| ES2650604T3 (es) | Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene |